** Dianthus Therapeutics' DNTH.O shares surge 13.2% on Tues to $36, highest since Apr 2022, adding to strong gain in previous session

** DNTH shares on Mon finished up 20% after co's mid-stage trial win for its muscle-weakening drug claseprubart

** After the bell Mon, co commenced $150 mln stock offering to fund preclinical and clinical development activities, and for working capital and general purposes

** Jefferies, TD Cowen, Evercore and Stifel are joint bookrunners for the offering

** Dianthus has ~32.19 mln shares outstanding for about $1.2 bln current market cap

** Raymond James early Tues hiked its PT by $7 to $63

** All 13 brokerages covering DNTH are bullish with "strongbuy" avg rating; median PT is $51.50, per LSEG data

** With the move on the session, shares up ~90% over the past three months, putting them up ~65% YTD

(Lance Tupper is a Reuters market analyst. The views expressed are his own)

((lance.tupper@tr.com 1-646-279-6380))